Novo Nordisk A/S (NYSE:NVO) Stock Price Down 1.9% - Here's What Happened

Key Points

• Novo Nordisk shares fell 1.9% to about $51.40 in mid-day trading, with ~13.58 million shares changing hands (a 2% rise vs. average); the stock is below its 200‑day moving average ($56.62) but above its 50‑day ($49.35), market cap ~$229.5B and P/E ~14.9.
• Analysts are mixed—MarketBeat shows a consensus rating of Hold with a consensus price target of $53.33, while individual ratings range from Strong Buy to Strong Sell.
• In the latest quarter Novo Nordisk beat EPS estimates ($1.02 vs. $0.77) but slightly missed revenue expectations ($11.79B vs. $11.98B), and reported strong profitability (net margin ~32.8%, ROE ~73.5%).

Novo Nordisk A/S (NYSE:NVO - Get Free Report) dropped 1.9% during mid-day trading on Monday . The company traded as low as $51.35 and last traded at $51.4030. Approximately 13,584,010 shares were traded during trading, an increase of 2% from the average daily volume of 13,353,102 shares. The stock had previously closed at $52.40.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Zacks Research cut shares of Novo Nordisk A/S from a "hold" rating to a "strong sell" rating in a report on Wednesday, December 3rd. Weiss Ratings restated a "sell (d+)" rating on shares of Novo Nordisk A/S in a research note on Monday, December 22nd. Rothschild Redb upgraded Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 16th. Argus reissued a "hold" rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Finally, Berenberg Bank upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have assigned a Hold rating and four have given a Sell rating to the company's stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of "Hold" and a consensus price target of $53.33.

Novo Nordisk A/S Trading Down 1.9%

The stock has a market capitalization of $229.51 billion, a PE ratio of 14.94 and a beta of 0.67. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. The stock has a 50 day moving average price of $49.35 and a 200-day moving average price of $56.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The company had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Institutional Investors Weigh In On Novo Nordisk A/S

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Lockheed Martin Investment Management Co. boosted its position in Novo Nordisk A/S by 179.4% in the second quarter. Lockheed Martin Investment Management Co. now owns 43,450 shares of the company's stock valued at $2,999,000 after buying an additional 27,900 shares during the last quarter. Martin Capital Partners LLC raised its position in Novo Nordisk A/S by 53.8% during the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company's stock worth $6,524,000 after buying an additional 41,129 shares during the last quarter. Acadian Asset Management LLC lifted its stake in Novo Nordisk A/S by 15,919.9% during the 1st quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company's stock valued at $72,523,000 after acquiring an additional 1,038,137 shares during the period. Unified Investment Management purchased a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at $692,000. Finally, Guild Investment Management Inc. increased its stake in shares of Novo Nordisk A/S by 20.7% in the second quarter. Guild Investment Management Inc. now owns 36,995 shares of the company's stock worth $2,553,000 after acquiring an additional 6,345 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company's core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.